Mindset Pharma is a leader in developing next-generation psychedelic medicines to treat neurological and psychiatric disorders.

ABOUT US

Company Overview

Mindset Pharma is a Toronto-based drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders.

Play Video

Pipeline

Mindset has developed 4 families of novel, next-generation psychedelics with differentiated characteristics and improved safety profiles. Read More

Click to enlarge

Family

Family 1 / MSP-1014: Psilocybin-like conjugate.

Family 2: High-potency, short-acting, psilocybin-like.

Family 3: Low-potency, long-duration for micro-dosing

Family 4: DMT/ 5-MeO-DMT-inspired compounds

Lead Identification

Lead Optimization

IND-Enabling

Clinical
Phase 1

Recent News

Jun 22, 2022
Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin
Jun 10, 2022
Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders
Jun 07, 2022
Mindset Pharma to Participate in Upcoming Conferences in June 2022
May 12, 2022
Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014
Subscribe for latest news